[6-K] Nasus Pharma Ltd Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Nasus Pharma Ltd. (NSRX) announced that it has appointed Eyal Rubin as its new Chief Financial Officer and Executive Vice President, effective November 19, 2025. The company entered into an Employment Agreement with him on the same date and expects to provide its standard indemnification agreement, similar to those for other directors and executive officers. The company states that there are no related party transactions involving Mr. Rubin that require disclosure. Mr. Rubin brings extensive experience from prior CFO roles at Protalix BioTherapeutics and BrainStorm Cell Therapeutics, and treasury leadership roles at Teva Pharmaceutical Industries. Nasus Pharma also issued a press release on November 20, 2025 announcing his appointment.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025 (Report No. 3)

Commission File Number: 001-42796

Nasus Pharma Ltd.

Yigal Alon 65

Tel Aviv, Israel 6744317

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

Appointment of Chief Financial Officer

On November19, 2025, Nasus Pharma Ltd. (the “Company”) appointed Mr. Eyal Rubin as the Company’s Chief Financial Officer (“CFO”) and Executive Vice President. In connection with Mr. Rubin’s appointment as CFO, the Company entered into an Employment Agreement, dated as of November 19, 2025, by and between the Company and Mr. Rubin (the “Employment Agreement”).

In connection with this appointment, the Company expects to enter into its standard form of indemnification agreement with Mr. Rubin on the same terms as the indemnification agreements previously entered into between the Company and each of its directors and executive officers. There are no related party transactions involving Mr. Rubin required to be disclosed under Item 7.B of Form 20-F.

Prior to joining the Company, from September 2019 to October 2025, Mr. Rubin served as Senior Vice President and Chief Financial Officer of Protalix BioTherapeutics, Inc. (NYSE American: PLX) (“Protalix”), where he led Protalix’s corporate finance, accounting, financial planning and operations. Prior to joining Protalix, he served as Executive Vice President and Chief Financial Officer of BrainStorm Cell Therapeutics Inc. (Nasdaq:BCLI), a publicly traded biotechnology company, where he was responsible for all corporate finance, accounting and investor relations activities. Prior to his role at BrainStorm, Mr. Rubin served at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; TASE:TEVA) in several roles, most recently as Vice President, Head of Corporate Treasury. In this role, Mr. Rubin was responsible for Teva’s cash operations and cash management, as well as Teva’s equity and debt capital markets transactions. Mr. Rubin holds a BA in Financing and IT Systems from the College of Management, Israel, where he graduated summa cum laude with a specialization in Financing and IT Systems, and an MBA from Bar-Ilan University, Israel, where he graduated summa cum laude with a specialization in Finance.

Press Release

On November 20, 2025, the Company issued a press release titled “Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer,” a copy of which is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K.

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release issued on November 20, 2025 by Nasus Pharma Ltd. titled “Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer”

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NASUS PHARMA LTD.
Date: November 20, 2025	By:	/s/ Dan Teleman
	Name:	Dan Teleman
	Title:	Chief Executive Officer

FAQ

What did Nasus Pharma Ltd. (NSRX) announce in this Form 6-K?

Nasus Pharma Ltd. announced the appointment of Eyal Rubin as its new Chief Financial Officer and Executive Vice President, effective November 19, 2025, and noted that it entered into an Employment Agreement with him on that date.

Who is the new CFO of Nasus Pharma Ltd. (NSRX)?

The new CFO and Executive Vice President of Nasus Pharma Ltd. is Eyal Rubin, who was appointed on November 19, 2025.

What prior experience does Eyal Rubin bring to Nasus Pharma (NSRX)?

Eyal Rubin previously served as Senior Vice President and Chief Financial Officer of Protalix BioTherapeutics, Inc. from September 2019 to October 2025, was Executive Vice President and Chief Financial Officer of BrainStorm Cell Therapeutics Inc., and held several roles at Teva Pharmaceutical Industries Ltd., most recently as Vice President, Head of Corporate Treasury.

Are there any related party transactions disclosed involving the new Nasus Pharma (NSRX) CFO?

The company states that there are no related party transactions involving Eyal Rubin that are required to be disclosed under Item 7.B of Form 20-F.

Did Nasus Pharma (NSRX) issue a press release about the CFO appointment?

Yes. On November 20, 2025, Nasus Pharma issued a press release titled “Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer”, which is furnished as Exhibit 99.1.

What agreements will Nasus Pharma (NSRX) enter into with the new CFO?

Nasus Pharma entered into an Employment Agreement with Eyal Rubin dated November 19, 2025 and expects to enter into its standard indemnification agreement with him on the same terms as for its other directors and executive officers.